Acrux

Azentio Software wins double honours at IBSi Global FinTech Innovation Awards 2023

Retrieved on: 
Monday, December 11, 2023
Islam, Senior, Cedar, Summit Bank, IBS, Islamic banking and finance, Accounting, Business process automation, Research, Intelligence, SLT, Automation, Apax Partners, Digital, Acrux, Capital market, IBM 7090/94 IBSYS, Core banking, Cryptocurrency, Bank

SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners, today announced that it won two awards at the 5th edition of the prestigious IBS Intelligence (IBSi) Global FinTech Innovation Awards 2023. The awards were formally presented at the Cedar-IBSi Summit on Digital & Core Banking, recently held in Mumbai.

Key Points: 
  • Awards recognize 'Impact-Generating Implementations' at Summit Bank, Pakistan and Vision Bank, UAE
    SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners , today announced that it won two awards at the 5th edition of the prestigious IBS Intelligence (IBSi) Global FinTech Innovation Awards 2023.
  • The awards were formally presented at the Cedar-IBSi Summit on Digital & Core Banking, recently held in Mumbai.
  • The Global FinTech Innovation Awards seek to honour banks, financial institutions, and technology players for their excellence in innovations using emerging technologies.
  • Applauding Azentio on winning the accolades, Nikhil Gokhale, Director - Research & Digital Properties at IBS Intelligence, said, "Congratulations to Azentio for their well-deserved wins.

Azentio Software wins double honours at IBSi Global FinTech Innovation Awards 2023

Retrieved on: 
Monday, December 11, 2023
Islam, Senior, Cedar, Summit Bank, IBS, Islamic banking and finance, Accounting, Business process automation, Research, Intelligence, SLT, Automation, Apax Partners, Digital, Acrux, Capital market, IBM 7090/94 IBSYS, Core banking, Cryptocurrency, Bank

SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners, today announced that it won two awards at the 5th edition of the prestigious IBS Intelligence (IBSi) Global FinTech Innovation Awards 2023. The awards were formally presented at the Cedar-IBSi Summit on Digital & Core Banking, recently held in Mumbai.

Key Points: 
  • Awards recognize 'Impact-Generating Implementations' at Summit Bank, Pakistan and Vision Bank, UAE
    SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners , today announced that it won two awards at the 5th edition of the prestigious IBS Intelligence (IBSi) Global FinTech Innovation Awards 2023.
  • The awards were formally presented at the Cedar-IBSi Summit on Digital & Core Banking, recently held in Mumbai.
  • The Global FinTech Innovation Awards seek to honour banks, financial institutions, and technology players for their excellence in innovations using emerging technologies.
  • Applauding Azentio on winning the accolades, Nikhil Gokhale, Director - Research & Digital Properties at IBS Intelligence, said, "Congratulations to Azentio for their well-deserved wins.

Tadhamon Bank gears up for the open banking era with Azentio Software's iMAL R14.5

Retrieved on: 
Monday, October 16, 2023
Partnership, Senior, Apax Partners, Islam, Digital, Record, Artificial intelligence, Acrux, Capital market, MENA, Blockchain, Software, Accounting, Cryptocurrency, Sharia

SINGAPORE, Oct. 16, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners announced today that Yemen-based Tadhamon Bank, one of the largest Islamic financial institutions in the Middle East and North Africa (MENA) region, upgraded to and is live with the latest version of iMAL, Azentio's industry-leading digital Islamic core banking platform.

Key Points: 
  • This cutting-edge version of iMAL with its key business functionalities and a flexible and agile core processing engine will accelerate Tadhamon Bank's transformation to a digitally advanced bank.
  • iMAL's multi-threading proficiencies at various levels, will deliver high data volume processing capabilities and enable parallel processing of records.
  • The bank can drive digital innovation and resource efficiency to create new opportunities for its business.
  • Qasem Mohammed, IT Manager at Tadhamon Bank, said, "Our bank has been running on iMAL since 2010.

Tadhamon Bank gears up for the open banking era with Azentio Software's iMAL R14.5

Retrieved on: 
Monday, October 16, 2023
Partnership, Senior, Apax Partners, Islam, Digital, Record, Artificial intelligence, Acrux, Capital market, MENA, Blockchain, Software, Accounting, Cryptocurrency, Sharia

SINGAPORE, Oct. 16, 2023 /PRNewswire/ -- Azentio Software ("Azentio"), a Singapore-headquartered technology firm owned by funds advised by Apax Partners announced today that Yemen-based Tadhamon Bank, one of the largest Islamic financial institutions in the Middle East and North Africa (MENA) region, upgraded to and is live with the latest version of iMAL, Azentio's industry-leading digital Islamic core banking platform.

Key Points: 
  • This cutting-edge version of iMAL with its key business functionalities and a flexible and agile core processing engine will accelerate Tadhamon Bank's transformation to a digitally advanced bank.
  • iMAL's multi-threading proficiencies at various levels, will deliver high data volume processing capabilities and enable parallel processing of records.
  • The bank can drive digital innovation and resource efficiency to create new opportunities for its business.
  • Qasem Mohammed, IT Manager at Tadhamon Bank, said, "Our bank has been running on iMAL since 2010.

New to The Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support

Retrieved on: 
Thursday, March 23, 2023
New Haven State Street station, Infection, CDI, Bloomberg Television, Interview, Newsmax TV, Clostridioides, Fear, Acrux, Nursing, Fox Business, Hospital, Patient, Digital, FDA, Social media, Television, Clostridioides difficile infection, Music, Pharmaceutical industry, Newsmax, Street

New to The Street's TV anchors will continue interviewing ACXP's management , discussing and introducing the Company's key business topics.

Key Points: 
  • New to The Street's TV anchors will continue interviewing ACXP's management , discussing and introducing the Company's key business topics.
  • Acurx Pharmaceuticals, Inc. is a clinical biopharmaceutical business developing a new class of antibiotics for bacterial infections.
  • The New to The Street's social media team and television network partners will re-share media content, creating a platform to increase awareness about Acurx.
  • On a schedule, show previews and commercial ads will air on selected New to The Street syndicated and sponsored TV platforms.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021
Russell Microcap Index, Program, QIDP, Absorption, HERE, Traction, CEO, Private Securities Litigation Reform Act, FDA, IPO, Minimum inhibitory concentration, Hand, Marketing, Patient, Infection, SMMT, Colon, Acrux, Ridinilazole, LLC, Optimism, Risk, Clinical trial, Kepler-86, Advertising, Daptomycin, Congress, NASDAQ, Stock dilution, Review, MIC, Death, Recurrence, Fast track (FDA), Goal, SEC, Research, HPM, Phase 3, Fine chemical, Risk management, Pharmaceutical industry, Antibiotics, Dietary supplement, Security (finance)

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021
Russell Microcap Index, Program, QIDP, Absorption, HERE, Traction, CEO, Private Securities Litigation Reform Act, FDA, IPO, Minimum inhibitory concentration, Hand, Marketing, Patient, Infection, SMMT, Colon, Acrux, Ridinilazole, LLC, Optimism, Risk, Clinical trial, Kepler-86, Advertising, Daptomycin, Congress, NASDAQ, Stock dilution, Review, MIC, Death, Recurrence, Fast track (FDA), Goal, SEC, Research, HPM, Phase 3, Fine chemical, Risk management, Pharmaceutical industry, Antibiotics, Dietary supplement, Security (finance)

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.